Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Success of experimental herpes vaccine builds momentum for human clinical trials

15.12.2004


A new study provides evidence that a herpes vaccine developed by a Harvard Medical School researcher is a strong candidate for testing in humans. The study, published online Dec. 14 in the Journal of Virology, compared three different experimental vaccines for herpes simplex virus 2 (HSV-2), the virus that causes most cases of genital herpes.



HSV-2 infects one in five Americans, and its prevalence has reached 50 percent in some developing countries, where it also seems to be helping to fuel the spread of HIV. HSV-2 infection, though incurable, typically does not cause major health problems, but can be life-threatening in immunocompromised people and newborn babies infected by their mothers.

Lead author Stephen E. Straus, MD, senior investigator in the Medical Virology Section in the Laboratory of Clinical Infectious Diseases at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, tested the vaccines in two established animal models of herpes infection. The HMS vaccine, developed by David Knipe, HMS professor of microbiology and molecular genetics, called dl5-29, outperformed the other two vaccines, one of which has already been tested in humans.


Straus said that the results argue strongly for taking dl5-29 into human trials. "Based upon d15-29’s biological and immunological properties, it appears to be the most compelling new vaccine candidate for genital herpes," he said.

Straus said that dl5-29 seemed especially promising because it solves a critical problem that is believed to underlie the failure of previous candidate vaccines. The dominant approach to herpes vaccine development over the past 20 years has been the delivery of one or two pure glycoproteins found in the outer envelope of the virus in order to induce an antibody response. But in trials of HSV-2 vaccines, a healthy antibody response has not seemed sufficient to protect against infection. One version of the herpes glycoprotein vaccine failed to protect research subjects from HSV-2 infection, while a second version of the glycoprotein vaccine failed to protect men, but showed a protective effect only in the subset of women who also had not been infected previously with HSV-1, the common cause of cold sores.

In contrast, dl5-29 is a live, mutant strain of HSV-2 that is missing two of the genes necessary for it to replicate and persist inside its host. "The proteins that are expressed are able to induce immune responses but the virus can’t spread," said Knipe, who is a coauthor on the paper. Normally, HSV-2 infects the cells lining genital areas, but makes its way into nearby sensory neurons, where it persists in a latent state. Because dl5-29 actually enters host cells and expresses many of its proteins within them, it not only elicits a broad spectrum of antibodies but also stimulates T cells, which directly attack infected host cells and release cytokines that further strengthen the immune response. The clinical trials of previous herpes vaccines suggested that T cells as well as antibodies must be activated to launch an effective defense.

Straus compared dl5-29 with a glycoprotein vaccine previously tested in humans and a third vaccine comprising a naked circular strand of DNA encoding the glycoprotein. Naked DNA vaccines have generated interest in recent years for their potential to elicit a stronger cellular immune response than by simply injecting the protein. Straus said that he tested dl5-29 against "the best tested standard vaccine plus the competing new concept in the field, DNA vaccines," in order to get a better sense of how well the dl 5-29 vaccine performed. His team tested the vaccines both in mice and in guinea pigs. The latter is the best model of human HSV-2 disease because it is the only one that mimics many of the aspects of the human disease, such as a recurring infection interspersed with periods of latency. The researchers studied how well the vaccines worked prophylactically-to prevent infection-and therapeutically to help control an existing infection.

Straus and his colleagues at the NIH found that in all measures dl5-29 performed as well or better than the other two candidates. It was as effective as the glycoprotein vaccine in preventing acute and recurrent disease in guinea pigs. Moreover, when given therapeutically to previously infected guinea pigs, dl5-29 reduced the rate of recurrent infections slightly better than the other candidates. A key finding was that dl5-29 also induced a substantially stronger T cell response than either of the two other vaccines.

Additionally, dl5-29 stimulated stronger antibody responses in animals than either of the other vaccines. Straus and Knipe said this result was surprising because it was thought that the large quantities of a single glycoprotein, as used in many recent human trials, was enough to stimulate sufficient levels of antibodies. Knipe said that as a live virus, dl5-29 produces many more viral proteins, and perhaps the resulting broader antibody response is important in preventing infection.

Because many other candidate vaccines have prevented infection in animals but failed in humans, the results do not guarantee success. But Straus observed that the stronger T cell response provides a major theoretical advantage for dl5-29 that could translate into greater clinical effectiveness in people. "The vaccine induced very good levels of immunity of the antibody type. It induced far better levels of immunity of the cellular type. It was enormously safe, and didn’t seem to persist in the animals," said Straus. "With dl5-29, we believe there are now sufficient data to justify clinical studies."

John Lacey | EurekAlert!
Further information:
http://www.hms.harvard.edu

More articles from Life Sciences:

nachricht Transport of molecular motors into cilia
28.03.2017 | Aarhus University

nachricht Asian dust providing key nutrients for California's giant sequoias
28.03.2017 | University of California - Riverside

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Challenging European Research Project to Develop New Tiny Microscopes

The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.

To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Researchers shoot for success with simulations of laser pulse-material interactions

29.03.2017 | Materials Sciences

Igniting a solar flare in the corona with lower-atmosphere kindling

29.03.2017 | Physics and Astronomy

As sea level rises, much of Honolulu and Waikiki vulnerable to groundwater inundation

29.03.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>